On December 28, 2017, the FDA (the U.S. Food and Drug Administration) gave approval for the Dermapace System, the Sanuwave shock wave device, intended to be used in the treatment of chronic, full-thickness diabetic foot ulcers. The device uses pulses of energy, similar to sound waves, to mechanically stimulate the wound.
DermaPACE is intended to be used in the wound areas measuring no larger than 16 cm2 which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. The device is intended for adult patients (22 years and older), presenting with diabetic foot ulcers lasting for more than 30 days, and should be used along with standard diabetic ulcer care.
For any further information visit the FDA official website.